相关临床试验
160
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1995
进行中（未招募）
6
3.8%
已完成
100
62.5%
No Longer Available
1
0.6%
尚未招募
4
2.5%
招募中
15
9.4%
终止
20
12.5%
Unknown
1
0.6%
撤回
13
8.1%
暂无批准数据
- The Barbara Ann Karmanos Cancer Institute will hold its fifth annual Screening Saves Lives event on Saturday, Oct. 3, 2026, from 9 a.m. to 1 p.m. at Karmanos Cancer Center in Detroit. - The event offers both insurance-based screenings (colonoscopy prep, low-dose CT lung screening, mammogram) and free walk-in screenings including head and neck, skin cancer, and wellness checks. - According to Metropolitan Detroit Cancer Surveillance System data, over 416 per 100,000 Detroit residents are diagnosed with cancer, with breast, lung, and colorectal cancers showing the highest incidence. - Early detection expands treatment options, and the event connects eligible women to free breast and cervical screenings through the Tri-County Breast & Cervical Cancer Control Program.
- Karmanos Cancer Institute treated 15,754 new cancer cases in FY2025, a more than 47% increase from 10,670 cases in 2020, marking the most new cases in its history. - The Institute opened 609 clinical trials and enrolled over 2,700 patients in interventional treatment studies between 2020 and October 2025, supported by more than $60 million in annual research funding. - Karmanos was the first cancer center worldwide to offer the TheraBionic P-1 device for liver cancer and the first in Michigan to provide lifileucel (TIL therapy) for metastatic melanoma. - The Institute recruited 43 scientists and clinicians since 2020 and earned a five-star CMS rating for nurse communication, achieved by only 13 hospitals in Michigan.
- The Barbara Ann Karmanos Cancer Institute has become the first and only independent cancer center in the U.S. to provide Etranacogene dezaparvovec-drlb (Hemegenix®), a one-time gene therapy for adults with hemophilia B. - Five-year clinical study results demonstrate that 94% of patients discontinued routine factor IX prophylaxis after receiving the gene therapy treatment. - The therapy works by delivering the factor IX gene through a viral vector that travels to the liver, enabling patients to produce their own clotting protein. - Eligible patients must currently use factor IX prophylaxis therapy and have current or historical life-threatening bleeding or repeated severe spontaneous bleeding episodes.
- PanTher Therapeutics has dosed the first patient in a Phase 1b clinical trial of PTM-101, an innovative thin film formulation of paclitaxel designed for direct tumor placement in pancreatic ductal adenocarcinoma. - The polymeric film delivers sustained high-dose chemotherapy for approximately six weeks with minimal systemic exposure, addressing the challenge that only 1% of systemically delivered chemotherapy typically reaches tumors. - Previous Phase 1 results showed promising tumor shrinkage with no detectable systemic paclitaxel exposure, demonstrating the potential to overcome dosing limitations of conventional chemotherapy. - The ongoing dose escalation study will evaluate PTM-101 at higher dose levels combined with standard FOLFIRINOX chemotherapy in approximately 30 treatment-naïve patients across multiple U.S. cancer centers.
- A second-generation BCMA-directed CAR T-cell therapy, MDC-CAR-BCMA001, demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma and AL amyloidosis, achieving a 5/6 overall response rate with 4 complete responses. - The novel therapy showed a favorable safety profile with manageable toxicity, including low incidence of severe cytokine release syndrome and no neurotoxicity, even in patients with significant organ dysfunction. - These promising results have prompted further investigation through ongoing clinical trials, including CARLOTTA001 (NCT05836896) and the CLEAR AL trial, potentially offering new hope for difficult-to-treat hematologic malignancies.
- Karmanos Cancer Institute is the first worldwide to prescribe the TheraBionic P1, an FDA-approved at-home device, for advanced hepatocellular carcinoma. - The TheraBionic P1 device delivers low-level radiofrequency electromagnetic fields to block tumor cell growth without harming healthy tissue. - Approved for patients who have failed first- and second-line therapies, the device offers a new systemic treatment option with minimal side effects. - Clinical studies have demonstrated that the TheraBionic P1 device can lead to tumor shrinkage and increased overall survival rates in HCC patients.
